Pfizer stops enrolment in Covid-pill trial after latest lousy results  

Pfizer has announced it will stop enrolment in a clinical trial for Paxlovid – its COVID-19 antiviral pill – for standard-risk COVID-19 patients after the latest results suggested the drug did not reduce symptoms or hospitalizations and deaths to a statistically significant degree.

Paxlovid, which consists of two different antiviral drugs – nirmatrelvir and ritonavir – is currently approved or authorized for conditional or emergency use in more than 65 countries, including the United States, to so called treat COVID-19 patients at high risk of severe illness, including hospitalization or death.

Pfizer said on June 14 that it will cease enrollment into the EPIC-SR trial due to low rate of hospitalization or death in the standard-risk population.

Related posts

Thousands march in Turkey to demand ban on LGBTQ groups


UK’s plans to govern use of digital identities revealed


Charles III becomes king of the United Kingdom and 14 other Commonwealth realms


Leave a Comment